News & Events

See what’s new at DiFilippo Corporate Finance Group

At DCF Group, we are continually working to advance the practice of financial and tax-related valuation issues to benefit our clients. Learn about new transactions, new staff members, industry news, and upcoming events. Check back often to see the latest updates.

News

Foghorn Therapeutics Announces Pricing of Initial Public Offering

Foghorn Therapeutics announced the pricing of its initial public offering of 7.50 million shares of its common stock. Read More
News

C4 Therapeutics Raises $182 Million in Upsized IPO

C4 Therapeutics priced its upsized initial public offering at $19 per share for gross proceeds of $182.4 million. Read More
News

Oncorus Announces Pricing of Initial Public Offering

Clinical-stage biopharmaceutical company announced the pricing of its IPO of 5.8 million shares of common stock. Read More
News

Relay Therapeutics Announces Closing of Initial Public Offering

Clinical-stage precision medicine company announced the closing of its IPO of 23 million shares of its common stock. Read More
News

Generation Bio Announces Closing of Initial Public Offering

Genetic medicines company announced the closing of its initial public offering of 12,105,263 shares of common stock. Read More
News

Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline

Cullinan Oncology announced Series B funding of $98.5 million, adding financial backing from institutional investors and family offices. Read More
News

Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered

Gene editing biotech Beam Therapeutics raised $180 million in its IPO after offering 48% more shares than anticipated. Read More
News

Black Diamond Therapeutics Doubles After $201 Million IPO

Black Diamond Therapeutics Inc. more than doubled in its trading debut after raising $201 million in an IPO that exceeded its goals. Read More